Continuing Education Activity
Platelet transfusion is a lifesaving procedure that is carried out to prevent bleeding or stop ongoing bleeding in patients with low platelet count or functional platelet disorders. There are minimum thresholds at which platelets are transfused in these patients, as not all low levels of platelet warrants a transfusion. Platelet is a scarce resource as processing, preparing, and transfusing it requires a great deal of precision and effort to maintain a certain quality. This activity highlights the use of platelet transfusion by the interprofessional team.
- Describe the platelet zones.
- Summarize the indications for a platelet transfusion.
- Review the complications of a platelet transfusion.
- Outline the strategies for improving the communication of the interprofessional team with respect to platelet transfusions.
Since the first attempted blood transfusion in the 17th century, blood transfusion has evolved from transfusing whole blood to utilizing only its components for select indications such as packed red blood cells (RBC), platelets, rarely white blood cells (WBC), frozen plasma and plasma-derived products. Platelets play an integral role in hemostasis by its response to vascular injury. The relevance of platelet component therapy was better understood in the 1950s and 1960s when severe and fatal hemorrhagic complications of chemotherapy in leukemia were studied.
In the middle of the last century, blood was collected in glass bottles, which depleted platelets on storage. Around the same time introduction of plastic bags revolutionized blood storage. It was also found to be gas permeable, which is essential for storing functional platelet. Over time, with the development of efficient separation techniques, platelet component with high platelet yield has been achieved with apheresis, changes in safety protocol reduced adverse outcomes of transfusions. A great deal has been done to minimize adverse outcomes, and further safety protocols are being explored.
Platelet concentrates (PC) are widely used to support patients with severe thrombocytopenia. These could be patients with hematologic malignancy, bone marrow failure, or other immune and non-immune causes of platelet destruction, though rare cases could warrant transfusion with normal platelet counts. Platelet is a scarce resource, partly because of its short shelf life of 5 days; it is classified in the World Health Organization’s (WHO) list of “Essential Medicine.”
Anatomy and Physiology
Platelets are anucleated discoid cells, size averaging between 2.0 to 5.0 micrometers in diameter, 0.5 micrometers in thickness with a mean cell volume of 6 to 10 femtoliters. Platelets are produced in the bone marrow through megakaryopoiesis from a hematopoietic stem cell (HSC) under the influence of thrombopoietin and appropriate growth factors, and an estimated ten thousand platelets are pumped into the circulation every single day. It has a life span of 8 to 10 days, after which structural changes on its surface are recognized by the liver where these senescent platelets are cleared from the circulation.
Platelets are primarily involved in the hemostasis by adhesion to the disrupted endothelium, secretion of mediators from its granules which promote aggregation, coagulation (by providing a surface to a host of proteins) and finally the clot retraction by the action of contractile proteins in the platelet together with its secretions and entrapped mesh of fibrin. Other roles played by platelet in the body include participation in the inflammation, mitogenesis, wound healing, and antimicrobial host deficiencies.
Structurally a platelet is divided into three zones:
- Peripheral zone - this zone is primarily involved in adhesion and aggregation function
- Glycocalyx - This is the thick carbohydrate-rich structure found on the exterior surface of platelets and serves as the site of the first contact during the hemostatic response by platelets, and it is made up of major and minor glycoproteins. GP-Ib-IX-V complex involved in adhesion at site of vascular injury. GPIIb-IIIa is involved in aggregation by attachment through fibrinogen to other platelets.
- Unit membrane - It is made of a lipid bilayer and open canalicular system, which serves a vital role in the acceleration of coagulation through the anionic phospholipid, phosphatidylserine, provided by the surface of activated platelets when clotting is initiated which converts prothrombin to thrombin.
- The submembrane area - It plays a vital role in transmitting signals from the surface to organelles in the cytoplasm regulating signal processes of platelet activation.
- Sol-gel zone - This is the matrix that is made of microtubules and microfilament, which plays a vital role in platelet structure and its support. This zone is responsible for various shape changes on activation during hemostasis and during ex vivo storage. Organelles are embedded within this matrix.
- Organelle zone
- Alpha-granules which stores fibrinogen fibronectin FV vWF, PDGF cytokines, chemokines, TG-beta-1 and VEGF
- Dense- granules stores calcium ATP, ADP, serotonin, and pyrophosphate
- Mitochondria- Are the powerhouse of platelets
- Lysosome and peroxisome
When a platelet is activated, secretions from the α and dense granules are involved in further platelet activation and aggregation. Secretions also have immune-mediated effects.
Normal platelet count in humans ranges from 150,000 to 450,000 cells/microliter. Platelet transfusion is mainly indicated to treat or prevent bleeding in patients with thrombocytopenia or platelet function disorder.
Platelet transfusion Threshold in Bleeding Patients
- <50,000 cells/microliter in severe bleeding including disseminated intravascular coagulation (DIC)
- <30,000 cells/microliter when bleeding, not life-threatening or considered not severe
- <100,000 cells/microliter for bleeding in multiple trauma patients or patients with intracranial bleed.
Prophylactic Transfusion Threshold
Prophylactic platelet transfusion is indicated below a specific threshold and is indicated before specific procedures or to prevent spontaneous bleeding. These include the following:
- To prevent spontaneous bleeding - transfuse at <10,000 cells/microliter, some recommend <5,000 cells/microliter
- Before neurosurgery or ocular surgery - <100,000 cells/microliter
- Before major surgery - <50,000 cells/microliter
- In DIC - <50,000 cells/microliter
- Before central line placement - <20,000 cells/microliter
- Before epidural anesthesia - <80,000 cells/microliter
- Before bronchoalveolar lavage (BAL) – 20,000 to 30,000 cells/microliter
- Before endoscopic procedures - <50,000 cells/microliter for therapeutic procedures; <20,000 cells/microliter for low-risk diagnostic procedures
- Vaginal delivery platelet transfusion is considered at <30,000 cells/microliter, and when traumatic delivery then <50,000 cells/microliter.
- Before lumbar puncture - <20,000 cells/microliter in patients with hematologic malignancies and 40,000 to 50,000 cells/microliter in patients without hematologic malignancies
- Platelet transfusion is not routinely indicated prior to bone marrow biopsy, peripheral, central catheter insertion, traction removal of tunneled central venous catheters, and cataract removal.
Platelet Transfusion in Specific Settings
- Idiopathic thrombocytopenic purpura (ITP) - transfusion is avoided unless severe bleeding is present.
- Malignancy and chemotherapy - In most cancers, platelet transfusion thresholds are as indicated above except in acute promyelocytic leukemia in which there is increased bleeding risk. Hence transfusion is indicated at counts <30,000 cells/microliter. chemotherapy is carried out at counts >20,000 cells/microliter.
- Cardiac surgery - Patients undergoing cardiac surgery get exposed to a blood-pumping circuit, which activates platelets that get destroyed once back in circulation; hence even at normal counts, platelet transfusion is indicated during cardiac surgery.
- Inherited and acquired platelet disorders like Glanzmann thrombasthenia, Bernard-Soulier syndrome, and other congenital platelet defects, acquired platelet disorders like patients with uremia or drug-induced platelet dysfunction. In these situations, platelet transfusion is indicated only when bleeding Is present.
- For pediatric patients, transfusion indications are otherwise similar in older infants and children compared to adults, as demonstrated by the PLADO study except in the following situation. We transfuse platelets when the platelet count is:
- <30,000 cells/microliter in neonates without any bleeding or symptom and failure to produce platelet.
- <50,000 cells/microliter in an infant with active bleed or undergoing an invasive procedure. For the same situation in a premature infant, we transfuse at <100,000 cells/microliter.
- Patient undergoing extracorporeal memebrane oxygenation (ECMO) and platelets <100,000 cells/microliter
The only agreed upon contraindication to platelet transfusion is thrombotic thrombocytopenic purpura (TTP) due to increased risk of thrombosis, although studies on outcomes and mortality have shown mixed results. Platelet transfusion is reserved for life-threatening bleeding only.
Heparin-induced thrombocytopenia (HIT) is another condition where platelet transfusion may increase the risk of thrombosis, but recent studies have shown no risk association. In HIT, transfusion is reserved only for pre-procedure or surgery, and in severe bleeding, prophylactic transfusion, however, is not indicated.
Platelets are transfused at the bedside through intravenous tubing with an in-line filter (screen filter of 170-260 micrometer pore size) to remove fibrin clots and large debris. The tubing can be primed with normal saline or blood product itself.
Emergency equipment as 0.9% normal saline, oxygen source, and emergency medication to treat anaphylaxis should be available at hand in case of transfusion reaction.
This involves multidisciplinary departments from clinician to the ancillary medical services. Platelet to be transfused is to be ordered by the physician and administered by the transfusions, which can be a nurse, who verifies the identity of the patient and match the unit before transfusing.
Preparation for platelet transfusion starts from the production of quality approved platelet concentrates (PC) in the blood banks. PC can be prepared from whole blood or by apheresis. 6 whole blood unit derived platelets equal one apheresis platelet which contains 3X10 platelets per unit, the shelf life of PC is five days within which it must be used. The normal dose of platelet transfused is calculated as 10 to 15 ml/kg of the patient.
The blood bank receives a request for transfusion from the physician with a pretransfusion sample, which is verified by the staff at both ends, following which ABO and Rh blood grouping is confirmed. PC is issued as and when required, which is mentioned on the blood request form. Group-specific PC is recommended, although out of the group can also be issued. When an emergency request for platelet transfusion is made, such as in traumatic bleeding patients, the patient blood group may not be available. In such cases, “AB” group platelets are given if available or else across the group transfusion is considered. Serologic crossmatch is not required except in rare cases where PC have high RBC content.
Consent from the patient must be obtained before sending a request to the blood bank, and the intravenous line must be set before the PC is issued from the blood bank. Staff at the issue counter does the final checks for details such as patient ID, unit no, blood group, and abnormal appearance or clumps suggestive of infection in the PC bag before issuing the unit.
Special requirements such as leukoreduction to reduce HLA alloimmunization or to minimize CMV transmission, irradiation to prevent transfusion-associated graft vs. host disease (TAGvHD) might be needed in specific patient groups. This special request is mentioned on the blood request forms.
The patient should have an appropriate IV cannula whose size ranges from 14G to 26G. In an adult, we normally use size 18G to 22G, while in the pediatric age group, it ranges from 25G to 26G. In rare cases where IV access is not available intraosseous route can also be used for transfusion.
Pretransfusion medication has been used in certain situations such as antihistamines in patients with a previous history of an allergic reaction during transfusion, occasionally meperidine or corticosteroid are occasionally ordered in patients with a history of severe rigors during transfusion.
The patient’s pretransfusion vitals are recorded by the transfusionist, thereafter connecting the PC bag by aseptically spiking the blood transfusion set to the IV line. A standard blood transfusion set with an inline filter of 170 to 260 micron is used. A transfusion rate of 2 to 5 ml/min is used, thereby completing the transfusion in 1 to 2 hours. Slower flow rates are used in patients at risk of fluid overload. The patient is closely monitored during the transfusion with the vitals recorded every 15 minutes if transfusion reaction is suspected at any point, the transfusion is stopped immediately with management protocol followed.
Platelet transfusion can be associated with complications. These complications can be immune-mediated such as febrile non-hemolytic transfusion reaction (FNHTR), allergic/anaphylaxis, TAGvHD, transfusion-related acute lung injury (TRALI), post-transfusion purpura, transfusion-related immunomodulation (TRIM), platelet refractoriness or non-immune mediated such as transfusion-associated circulatory overload (TACO), physical injury, sepsis, viral infection transmission, hypotensive reaction.
Febrile Non-Hemolytic Transfusion Reaction (FNHTR)
FNHTR is a relatively common complication with a frequency of 4% to 30%. It is characterized by the temperature rise of ≥1°C within the first 4hr of transfusion, which resolves within 48 hours, there can be associated with nausea, vomiting, dyspnoea, and hypotension.  Antibodies against HLA or leukocyte antigen in donor plasma are most commonly implicated. Antigen present on donor white cells binds to the antibody in the recipient, which leads to pyrogen and cytokine release such as TNF-alpha, IL1, and IL6. FNHTR can also occur due to biologic response modifiers (BRM) released during platelet storage, which is increased with storage. Platelet has maximum storage allowed for five days during which the release of substances such as CD40L, IL6, and IL8 can occur. FNHTR is diagnosed with the above-mentioned features and the possibility of chills, hemolytic causes are ruled out by further immunohematology work up and lab findings. FNHTR can be minimized by leukoreduction and by platelet additive solution (PAS), which replace maximum plasma in stored platelets.
Allergic and Anaphylaxis
An allergic reaction is similar to FNHTR, and its frequency is between 0.09% and 21%. It manifests as pruritus, urticaria, or systematically as bronchoconstriction and seldom associated with fever. Pathogenesis is heterogeneous in origin ranging from proteins, antibodies, cytokines to BRM released during storage.
Anaphylaxis can occur when the patient is IgA deficient and has antibodies against it and receives IgA containing platelets, and this occurs 1 in 50,000 transfusions. Diagnosis is made clinically, and it is an emergency.it can be prevented by giving washed platelets or platelets obtained from IgA deficient donor.
Allergic reactions can be minimized by depleting plasma in platelets.
Transfusion-associated Graft vs. Host Disease
This a rare but fatal complication characterized by fever and multiple systemic manifestations such as skin, gastrointestinal tract, liver, and others. It is caused by the transfusion of viable lymphocytes that get a favorable environment in the recipient, where they engraft and proliferate subsequently attacking the host tissues. It can occur between 1 to 6 weeks from transfusion and occurs in an immunocompromised host, those with congenital T-cell defects, population with low genetic diversity (homozygous HLA), or first-degree patient relatives. Symptoms involve multiple organs as skin, the intestine, liver, and suppression of bone marrow. Diagnosis is that of exclusion and requires molecular methods of testing apart from microscopic features seen. This can be prevented by the irradiation of platelets.
TRALI is another rare complication associated with the development of respiratory failure after ruling out other possible causes. Mainly caused by transfusion of antibodies in the plasma from the donor against HLA or human neutrophil antigens, an example is a platelet donated by a multiparous woman. TRALI occurs within 6 hours of transfusion. These patient develop acute worsening respiratory symptoms with characteristic features as hypoxemia: PaO/FIO ≤ 300 mm Hg with oxygen saturation <90%, all other causes of acute lung injury are ruled out before considering TRALI, it can be minimized by reducing plasma in platelets transfused such as the use of PAS.
Post Transfusion Purpura
A rare syndrome with a sudden drop in platelet count within 1 to 21 days of platelet transfusion, it is a self-limiting condition associated with wet purpura. Believed to be caused by autoantibody formation as a complication to platelet transfusion.
The presence of leukocytes and biologic response modifiers released during storage have been implicated in immunomodulation. TRIM leads to a modified response of TH1/Th2 T-cells, which predisposed the patient to infection and delayed recovery from surgery. This can also be prevented by prestorage leukoreduction and depleting plasma from platelets.
This occurs when post-transfusion platelet recovery is not as expected. Though multiple causes can be there ranging from immune to non-immune, a multi transfused patient can develop antibodies against specific HPA(human platelet antigens) or HLA antigens. These antibodies are implicated in platelet refractoriness.  the antibodies cause platelet destruction by the immune system; in such patients, platelet crossmatching can reduce the incidence. HLA matched platelets, or if anti-human platelet antigen(HPA) antibody is involved matching HPA antigen is indicated.
Transfusion Associated Circulatory Overload
This adverse reaction is more likely in the pediatric group and patients with cardiac insufficiency. Slow transfusion with close monitoring in risk group is recommended
This is possible at the site of intravenous access, which can cause complications like hematoma or nerve injury.
Sepsis and Bacterial Infection
Platelet concentrates are stored up to 5 days at temperatures 22 to 24 degrees C. This temperature is favorable for the growth of bacteria like Staphylococcus aureus and gram-negative bacteria. Possible sources of infections can be improper cleansing of donor phlebotomy site or if a donor has asymptomatic bacteremia. The risk of infection to the patient ranges from 0.14% to 1.41% with platelet transfusion. Pathogen reduction technology has been used to minimize infections in plasma and platelets.
Transmission of Viral Infection
All blood donations are screened for HIV, HCV, and HBV with other virus screening depending on the region. There remains a residual risk of transmission, as not all donors in the window period are detected. There is a possibility of transmission of infection by other viruses that are not routinely screened in the blood bank, more so of emerging infections. Pathogen reduction technology has been used to reduce this risk, but it’s not effective against all types of viruses.
Patient on ACE inhibitors who receive bedside leukoreduction is at risk of hypotension. Exposure of the blood component to the negatively charged surface of the filter produces vasoactive bradykinin related peptides, and this occurs within 5 minutes of transfusion. With ACE inhibitors present in the patient, these peptides are not metabolized, leading to hypotension. A proper history of medications before transfusion is important.
Platelets are a blood component that still does not have a substitute as its functions are complex. As described above, the process of collecting, processing, storing, and transfusing platelets is a multidisciplinary process requiring skill and precision. Nevertheless, platelet transfusion has it’s own risks, though risk vs. benefit assessment is done before requesting its transfusion. Minimizing the risk in platelet transfusion and improving the outcomes is an evolving aspect in the field of transfusion medicine.
Enhancing Healthcare Team Outcomes
Physicians requesting any component for transfusion should always consider platelet a scarce resource and only request it when absolutely necessary. Special request such as irradiation, leukoreduction, or plasma depletion of platelets could be discussed with the transfusion specialist as these modifications of platelet has specific indications and also burdens the transfusion services. Regular audits on blood usage can help improve patient outcomes. Regular continuing medical education for technical and nursing staff on safe transfusion can improve transfusion services and the care a patient receives. Always keep in mind that with every transfusion, there is an additional potential risk to the patient.
Hemovigilance network in every country or region keeps a record of all adverse events and can be used as a source of information for improving guidelines and transfusion policy in a given region. Hence the importance of implementing a strong hemovigilance system that is lacking in many countries or regions.
Guidelines to platelet transfusion have been formulated based on randomized controlled trials and meta-analysis, one such guideline is provided by the British journal of hematology. These guidelines should be implemented in our clinical practice to enhance patient care.
Nursing, Allied Health, and Interprofessional Team Interventions
Nurses are an integral part of any clinical practice, they are present at the fore front. there proper training and regular education become vital in maintaining transfusion safety as they can be a barrier to preventing/identifying an error/adverse event. A good understanding between the specialities is important to provide the best possible patient care.